Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AES Corp (AES) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

AES Corp vs State Street SPDR S&P Biotech ETF — how do they compare? AES Corp trades at $14.73 (market cap $10.49B), while State Street SPDR S&P Biotech ETF trades at $159.2. The key difference: AES Corp pays a 4.79% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, AES Corp nearer its low. Which is the better fit depends on your goals.

AESXBI
Market Cap
$10.49B
Sector
UtilitiesBroad Market / Factor
52-Week High
$17.28$164.28
52-Week Low
$12.51$86.92
Enterprise Value
$40.75B
Dividend Yield
4.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AES Corp

AES trades at $14.725, down 0.03% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 14.34% net income margin and a low P/E of 5.51. Recent news highlights a pending $33.4 billion acquisition by a consortium led by Global Infrastructure Partners and EQT, approved by stockholders in June 2026, alongside a quarterly dividend of $0.17595 per share.

The stock offers a high dividend yield and appears undervalued based on earnings, but faces risks from the acquisition's regulatory scrutiny and a recent earnings miss. Upside is capped near the $15 buyout price if the deal closes, while downside exists if approvals fail. Analyst sentiment is mixed with no sell ratings but a majority on hold.

State Street SPDR S&P Biotech ETF

XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.

The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.

Returns comparison

Trailing returns across standard periods

About AES Corp

AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.

Read more on AES

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI